NCT07246681

Lignin in Treatment of Helicobacter Pylori Infection

Role of Lignin in Treatment of Helicobacter Pylori Infection: A Double-blind Placebo-controlled Study

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Zagazig University · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if drug hydrolyzed lignin works to treat H pylori infection in adults. It will also learn about the safety of drug lignin n the sitting of H pylori infection, and if it halts the side effects associated with H pylori triple therapy. The main questions it aims to answer are: * Does drug hydrolyzed lignin improve the H pylori eradiation rate when it is added to the standard triple therapy used in treatment of H pylori? * What medical problems do participants experience when taking drug hydrolyzed lignin? Researchers will compare drug hydrolyzed lignin to a placebo (a look-alike substance that contains no drug) to see if drug hydrolyzed lignin works to treat H pylori. Participants will: * Take drug hydrolyzed lignin or a placebo every day for 2 weeks beside the standard triple therapy * Visit the clinic once every 1 week for checkup and questionnaire filling * Check for H pylori eradication after treatment

Conditions

• HELICOBACTER PYLORI INFECTIONS

Interventions

Type	Name	Description
DRUG	Hydrolyzed Lignin	The drug will be supplied randomly to the group I
OTHER	Placebo	Will be supplied randomly to Group II

Timeline

• Start date: 2025-10-31
• Primary completion: 2026-02-15
• Completion: 2026-03-15
• First posted: 2025-11-24
• Last updated: 2025-11-24

Locations

1 site across 1 country: Egypt